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Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it 
is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult 
patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/
day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment 
with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at 
the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis 
that treatment protocols with lower BNZ doses may be effective.
Key words: pharmacology - Chagas disease - benznidazole
doi: 10.1590/0074-02760150401
Financial support: ANLIS CG Malbran, Health Ministry of Argen-
tina, CONICET
MEM has a fellowship, and FGB, GM, JA, and AGS are members of 
CONICET.
+ Corresponding author: marisa.fernandez@gmail.com
Received 20 October 2015
Accepted 3 February 2016
Chagas disease, a zoonotic disease affecting six mil-
lion people in Latin America, is caused by the haemofla-
gellate protozoan known as Trypanosoma cruzi (WHO 
2015). Treatment for Chagas disease, developed more 
than 40 years ago, is highly effective during the acute 
phase of the infection and in chronically infected chil-
dren (de Andrade et al. 1996, Sosa-Estani et al. 1998), 
but its efficacy in the chronic stage in adults is still sub-
ject of intense controversy (Villar et al. 2014). However, 
trypanocidal treatment for chronic Chagas disease has 
increased in the past decade due to recommendations by 
multiple national and international organizations.
Benznidazole (BNZ) is currently considered the try-
panocidal drug of choice for the treatment of Chagas dis-
ease, and nifurtimox a valid alternative option. Limited 
human data is available for both drugs, leading to a lim-
ited understanding of their clinical pharmacology, partic-
ularly of the mechanisms involved in the therapeutic re-
sponse and the high rate of adverse drug reactions (ADRs) 
(Castro et al. 2006, Hasslocher-Moreno et al. 2012).
We studied six adult patients with Chagas disease 
treated with the new BNZ formulation, ABARAX®. 
Chagas disease was diagnosed by means of at least two 
positive serological tests for T. cruzi (indirect immunoflu-
orescence, enzyme immunoassay and/or indirect haemag-
glutination). None of the patients had received trypano-
cidal treatment before. All patients presented laboratory 
tests within normal values and a negative pregnancy test 
for women in reproductive age. During treatment, patients 
were advised to follow a low fat diet, excluding histamin-
ergic foods and alcohol. Contraception was also indicated 
for women in reproductive age. Clinical laboratory tests 
(haemogram, liver enzymes, and renal function tests) 
were obtained at 25 and 45 ± 5 days of treatment; medi-
cal follow-up visits were planned at 35 ± 7 days. Real-
time PCR for satellite and kinetoplastid DNAs of T. cruzi 
(Ramírez et al. 2015) were done before treatment, at the 
end of treatment, and after six months of follow-up as an 
early surrogate biomarker of potential for treatment fail-
ure (Molina et al. 2014, Morillo et al. 2015, Pinazo et al. 
2015). This study was approved by Bioethics Committee 
of Fatala Chaben Institute on 1 August 2013; our ethics 
review board does not provide protocol.
Treatment was scheduled according to current adult 
treatment guidelines (MSAL 2012). Blood extractions 
for therapeutic drug monitoring were done under ex-
press patient consent, but considered part of required 
therapeutic measures. Plasma samples were obtained 
pre and post-doses, for therapeutic drug monitoring pur-
poses, during steady state phase of the drug (i.e., at least 
after 48 h or after four half-lives from the start of the 
treatment). BNZ was measured in plasma using a previ-
ously published high-performance liquid chromatogra-
phy method (Marson et al. 2013). All patients consented 
to the procedures and treatment.
BNZ doses ranged from 4.12-5.50 mg/Kg/day in four 
patients and 2.50-2.60 mg/Kg/day in two patients (pa-
tients 1 and 2) who did not follow medical indications 
and took half the prescribed dose (i.e, 100 mg bid instead 
of 200 mg bid) (Table I).
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Measured plasma BNZ concentrations ranged from 
4.6-15.0 mg/L (Table II). Ratio of plasma BNZ concentra-
tion (mg/L)/BNZ administered dose (mg/Kg/day) showed a 
narrow range of values, from 1.0-3.0 mg/L of BNZ per mg 
of drug administered, except for patient 1 (Figure, Table II).
Patient 1, who took half the prescribed dose (i.e., 2.5 
mg/Kg/day BID), had BNZ plasma levels higher than 
those patients taking full dose. This patient was not tak-
ing any other medications, nor had any diseases or con-
ditions known to affect BNZ pharmacokinetics. Actual 
dosage was confirmed by pill counts (number of BNZ 
tablets in the pill bottle was compatible with the patient 
taking a reduced dose, i.e, twice the number of tablets 
expected were observed in the bottle) and intensive re-
viewing of drug intake history with the patient.
Patient 2, who also took half the prescribed BNZ 
dose, had BNZ concentrations compatible with this dos-
age (Table II). In spite of lower BNZ plasma levels, this 
patient showed an appropriate parasitic response to BNZ 
[i.e., nondetectable quantitative polymerase chain reac-
tion (qPCR) for parasite DNA at six months follow-up].
In addition, three out of six patients [patients 2, 5, 
and 6 (Table I)] had positive qPCRs for T. cruzi SatDNA 
and kDNA at baseline, whereas all patients in this series 
had nondetectable qPCR at the end of treatment and at 
six months of follow-up for both qPCR methods. Four 
patients developed ADRs during treatment and two pa-
tients had severe ADRs which required treatment dis-
continuation (patients 3 and 4). A relationship between 
plasmatic BNZ dosage and ADRs was not observed in 
this small number of cases.
Historically, medication availability has been one of 
the most important health issues related to neglected dis-
eases such as Chagas disease. BNZ was developed and 
produced by Roche until 2011 when production was dis-
continued (Jannin & Villa 2007). BNZ production was 
later taken up by the Brazilian pharmaceutical company 
LAFEPE and Argentinian laboratory ELEA. The latter 
developed a new BNZ formulation named ABARAX®, 
which was fast-tracked by the Argentine National Food, 
Drug, and Medical Technology Agency due to the ur-
gent problem of re-establishing an adequate BNZ sup-
ply (Navarro et al. 2012). Unfortunately, emergency ap-
proval of the new formulation and the fact that there is 
no stock of the original drug formulation produced by 
Roche meant that no bioequivalence studies were car-
ried out (ANMAT 2012). This situation leads to a lack 
of pharmacological data on drug bioavailability to guide 
dose adjustments of the new formulation.
We observed no relationship between plasma BNZ 
values and occurrence of adverse events or their sever-
ity in this limited small series. This observation is in line 
with previous similar studies (Pinazo et al. 2013, Salvador 
et al. 2015). However, a remarkably high rate of ADRs 
was observed in our patients group. All patients studied 
had nondetectable T. cruzi SatDNA and kDNA qPCRs at 
the end of treatment and at six months follow-up, includ-
ing those who could not complete treatment due to ADRs 
and those who had lower BNZ plasma levels. This obser-
vation shows probably parasitological responses to BNZ 
treatment even at lower exposures and provides further 
support to the hypothesis that treatment protocols with 
lower BNZ doses could be effective, as suggested by pre-
vious observations in children (Altcheh et al. 2011) and 
adults treated with different BNZ formulations. Moreover 
in silico models, computer simulations of biological mod-
els show that a lower dose (2.5 mg/kg/d) would be enough 
to achieve minimum plasma concentrations within the 
proposed therapeutic BNZ range between 3-6 mg/L (Soy 
et al. 2015). Lower doses may have, at least in theory, the 
advantage of a lower incidence of ADRs, the primary 
cause of discontinuation of drug treatment.
TABLE I
Clinical features of treated patients
Patient
ID
Age 
(years)/gender
Place of  
birth
BNZ dose  
(mg/kg/day)
BNZ 
treatment 
(days)
SatDNA and 
kDNA qPCRs Adverse drug reactions
1 45/M Paraguay 2.60 60 ND/ND/ND 10th day: mild dermatitis
53rd day: mild myalgia in lower limbs
2 33/F Argentina 2.50 60 NQ/ND/ND 45th day: pruritus
24th day after EOT: cervical lymph node pain
3 33/M Argentina 5.48 23 ND/-/ND 13th day: mild dermatitis
23rd day: oral mucositis, dysgeusia, and 
paresthesia in lower limbs
4 29/F Bolivia 4.12 32 ND/ND/- 9th day: pruritus  
26th day: liver enzymes 20 times UNL,  
hypereosinophilia
5 21/M Bolivia 4.55 60 NQ/ND/ND Not observed
6 31/M Bolivia 4.55 60 NQ/ND/- Not observed
BNZ: benznidazole; EOT: end of treatment; F: female; M: male; ND: nondetectable; NQ: nonquantifiable (time of measurement: 
baseline/end of treatment/6 month of follow-up); qPCR: quantitative polymerase chain reaction; UNL: upper normal level.
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We have no clear explanation for the observed phar-
macokinetic behaviour in the patient who disclosed tak-
ing half BNZ dose but had BNZ plasma levels higher than 
patients treated with a full BNZ dose. Unfortunately, little 
is known about what factors that may affect BNZ phar-
macokinetics. Considering that the patient’s dosage was 
compatible with the number of tablets left in his pill bottle 
and that he was not receiving any other medications nor 
had any clinical conditions that could affect BNZ elimina-
tion, we may speculate that it is possible that this patient 
had a polymorphism, hitherto unknown, in the molecular 
mechanisms involved in the elimination of BNZ that could 
have led to accumulation to higher concentrations than ex-
pected. This is a tantalising possibility that we are current-
ly exploring, but research in this area is significantly ham-
pered by the lack of knowledge on absorption mechanisms, 
metabolism, and elimination pathways of BNZ up to date.
This study suggests that BNZ responses continue to 
be high with the currently available BNZ formulation 
(ABARAX®) and provides new support to the hypoth-
esis that treatment protocols with lower BNZ doses may 
still be effective. Preliminary observations in one of our 
patients suggest polymorphic behaviour in the elimina-
tion of the drug, which needs to be further explored in 
clinical and basic studies.
TABLE II
Pharmacometric parameters of patients
Patient
ID
Time in 
BNZ treatment 
(day)
Plasma samples 
(times per patient)
Sampling time
 after last intake 
(hours)
Plasmatic BNZ
(mg/L)
Plasmatic BNZ 
(mg/L)/
BNZ daily dose 
(mg/Kg)
1a,b 53 1/1 1.1 8.1 ± 0.1 3.12
1/2 2.7 12.5 ± 0.6 4.81
55 2/1 1.0 11.6 ± 0.3 4.46
2/2 2.5 15.0 ± 0.2 5.77
60 3/1 1.1 11.5 ± 0.1 4.42
3/2 3.1 8.2 ± 0.1 3.15
2a 60 0 0.0 4.6 ± 0.1 1.84
1 1.0 4.9 ± 0.1 1.96
2 2.0 5.1 ± 0.1 2.04
3c 5 0 0.0 5.7 ± 0.5 1.04
1 1.0 7.1 ± 0.1 1.30
2 2.0 6.8 ± 0.1 1.24
4c 5 0 0.0 7.3 ± 0.1 1.77
1 1.0 8.4 ± 0.1 2.04
2 2.0 12.0 ± 0.3 2.91
5 17 0 0.0 7.5 ± 0.1 1.65
1 1.0 8.1 ± 0.1 1.78
2 2.0 9.7 ± 0.3 2.13
6 5 0 0.0 7.1 ± 0.1 1.56
1 1.0 9.4 ± 0.1 2.07
2 2.0 9.3 ± 0.1 2.04
a: patients 1 and 2 - 2.5 and 2.6 mg/kg/day dose; b: patient 1 had two samples per day from three different days; c: patients 3 and 
4 - treatment was interrupted; BNZ: benznidazole.
Ratio of plasma benznidazole (BNZ) concentration (mg/L)/BNZ ad-
ministered dose (mg/Kg/d) during steady state phase. Patient 1 had 
two samples per day from three different days showed a high ratio 
of BNZ concentration all the times (1/1: patient 1, samples day 1; 
1/2: patient 1, samples day 2; 1/3: patient 1, samples day 3). Patient 2 
took half the indicated dose, her plasma drug concentration was nor-
malised according to BNZ administered dose, and presented similar 
ratio as the rest of the patients of the series (patients 3, 4, 5, and 6).
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